首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   95449篇
  免费   8595篇
  国内免费   4045篇
耳鼻咽喉   280篇
儿科学   1793篇
妇产科学   498篇
基础医学   7313篇
口腔科学   541篇
临床医学   11674篇
内科学   10632篇
皮肤病学   279篇
神经病学   6168篇
特种医学   5188篇
外国民族医学   74篇
外科学   14217篇
综合类   18081篇
现状与发展   8篇
一般理论   1篇
预防医学   4583篇
眼科学   764篇
药学   8329篇
  75篇
中国医学   4693篇
肿瘤学   12898篇
  2025年   23篇
  2024年   1428篇
  2023年   2271篇
  2022年   3438篇
  2021年   4746篇
  2020年   4370篇
  2019年   3623篇
  2018年   3377篇
  2017年   3834篇
  2016年   3957篇
  2015年   3914篇
  2014年   6291篇
  2013年   6915篇
  2012年   5678篇
  2011年   6197篇
  2010年   5146篇
  2009年   4728篇
  2008年   4668篇
  2007年   4759篇
  2006年   4440篇
  2005年   3838篇
  2004年   3029篇
  2003年   2684篇
  2002年   2203篇
  2001年   1969篇
  2000年   1587篇
  1999年   1268篇
  1998年   1105篇
  1997年   1057篇
  1996年   874篇
  1995年   694篇
  1994年   595篇
  1993年   468篇
  1992年   463篇
  1991年   353篇
  1990年   316篇
  1989年   262篇
  1988年   218篇
  1987年   197篇
  1986年   187篇
  1985年   185篇
  1984年   137篇
  1983年   88篇
  1982年   99篇
  1981年   99篇
  1980年   90篇
  1979年   68篇
  1978年   32篇
  1977年   38篇
  1976年   27篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
目的 分析重庆市肺癌发病死亡和疾病负担归因于被动吸烟的情况,为开展肺癌防治提供建议。 方法 肺癌死亡个案数据来源于2019年重庆市肿瘤登记报告系统,被动吸烟率来自2013年重庆市慢性病及危险因素监测。计算人群归因危险度百分比(population attributable risk percent, PAR%)、被动吸烟导致的肺癌发病、死亡和疾病负担。采用Excel 2010与SPSS 25.0进行统计分析,率的比较采用χ2检验。 结果 2013年30岁及以上成年人被动吸烟率为52.37%。2019年重庆市30岁及以上人群肺癌发病率与标化发病率分别为118.44/10万与80.83/10万,死亡率与标化死亡率分别为96.51/10万、63.58/10万。肺癌发病率和死亡率归因于被动吸烟的PAR%分别为19.76和19.04,归因发病率与归因标化发病率分别为23.41/10万和16.34/10万,归因死亡率与归因标化死亡率分别为18.38/10万和12.40/10万。2019年重庆市30岁及以上肺癌早死所致寿命损失年率(years of life lost,YLL)、残疾所致寿命损失年率(years lived with disability,YLD)、调整伤残寿命损失年率(disability adjusted life year,DALY)分别为21.16‰、0.31‰、21.47‰,YLL率、YLD率、DALY率归因于被动吸烟的PAR%分别为21.16、19.76和20.49,归因YLL率为4.34‰,归因YLD率为0.06‰,归因DALY率为4.40‰。 结论 2019年重庆市30岁及以上人群肺癌发病率、死亡率、YLL率、DALY率高,被动吸烟率高,肺癌归因于被动吸烟的疾病负担重,应加强落实控烟工作。  相似文献   
2.
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone.  相似文献   
3.
目的探讨不同程度碘对比剂后急性肾损伤的危险因素及其转归预后。方法筛选2016年4月1日至2019年8月31日于重庆医科大学附属第三医院住院期间发生碘对比剂后急性肾损伤(PC-AKI)的患者,按照急性肾损伤分层标准将其分为非严重损伤组(A组)和严重损伤组(B组),从基本人口学资料、基础疾病、药物使用情况、转归预后等方面分析两组患者的特点及差异。结果 1 920例患者中发生PC-AKI者90例,其中A组72例(80.00%),B组18例(20.00%),B组中最终需肾脏替代治疗(血液透析)干预者11例(12.22%)。A组与B组间一般情况、基础肾功能、碘对比剂的使用以及联用肾毒性药物、静脉水化量等观察指标无统计学差异。B组合并慢性疾病者更多,其中冠心病(55.56%vs 29.17%)、心肌梗死(27.78%vs 5.56%)患病率差异具有统计学意义(P<0.05),行血液透析的患者第一诊断为心肌梗死者占45.45%。65.85%的患者在使用对比剂后10 d内肌酐仍高于基线,54.54%的透析患者在出院时仍需透析治疗,81.81%的透析患者出院时死亡或放弃治疗。结论合并冠心病、心肌梗死的患者更容易发生严重PC-AKI,当合并这些疾病的患者使用碘对比剂时,临床医师应密切关注其肾功能的变化。PC-AKI的肾功转归较差,发生PC-AKI后需透析治疗的患者往往预后不良。  相似文献   
4.

Aims

Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.

Materials and methods

One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.

Results

In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.

Conclusion

Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial.  相似文献   
5.
Objective: The purpose was to describe the prevalence and characteristics of healthcare utilization among individuals with spinal cord injury (SCI) from a Level I trauma center.

Design: Retrospective data analysis utilizing a local acute trauma registry for initial hospitalization and merged with the Dallas-Fort Worth Hospital Council registry to obtain subsequent health care utilization in the first post-injury year.

Setting: Dallas, TX, USA.

Participants: Six hundred and sixty four patients were admitted with an acute traumatic SCI from January 2003 through June 2014 to a Level I trauma center. Fifty five patients that expired during initial hospitalization and 18 patients with unspecified SCI (defined by ICD-9 with no etiology or level of injury specified) were not included in the analysis, leaving a final sample of 591.

Outcome Measures: Data included demographic and clinical characteristics, charges, and healthcare utilization.

Results: Mean age was 46.1?years (±18.9?years), the majority of patients were male (74%), and Caucasian (58%). Of the 591 patients, 345 (58%) had additional inpatient or emergency healthcare utilization accounting for 769 additional visits (median of 3 visits per person). Of the 769 encounters, 534 (69%) were inpatient and 235 (31%) were emergency visits not resulting in an admission. The most prevalent ICD-9 codes listed were pressure ulcer, neurogenic bowel, neurogenic bladder, urinary tract infection, fluid electrolyte imbalance, hypertension, and tobacco use.

Conclusion: Individuals with SCI experience high levels of healthcare utilization which are costly and may be preventable. Increasing our understanding of the prevalence and causes for healthcare utilization after acute SCI is important to target preventive strategies.  相似文献   

6.
7.
《Cancer cell》2021,39(9):1279-1291.e3
  1. Download : Download high-res image (205KB)
  2. Download : Download full-size image
  相似文献   
8.
9.

Objective

Vascular sealing with an energy vessel sealing system during lung resection may allow surgeons to treat small vessels with minimal dissection, possibly decreasing likelihood of injury. Few large prospective trials have examined the proximal sides of vessels not ligated in addition to sealing during surgery. We therefore assessed feasibility of an energy device to seal pulmonary artery and vein branches without further ligation.

Methods

This prospective, preoperative registration study at 2 institutions evaluated safety of energy sealing with the LigaSure (Medtronic, Minneapolis, Minn), with no additional reinforcing material such as suture ligation, for pulmonary vessels as large as 7 mm during anatomic lung resection (cohort 1 study). A postoperative hemorrhage occurred in the 128th case, so a cohort 2 study proceeded after we changed inclusion criterion for pulmonary arteries from a maximum of 7 mm to a maximum of 5 mm.

Results

In cohort 1 (n = 128) and cohort 2 (n = 200), 216 and 250 pulmonary arteries and 189 and 213 pulmonary veins, respectively, were treated with energy sealing. Overall postoperative hemorrhage rate was 0.3% (1/328 patients); however, no serious postoperative complications were associated with energy sealing among the 200 patients in cohort 2. Subsequent inspection of the torn artery stump confirmed that the bleeding in the 128th case was in an area adjacent to the sealing zone.

Conclusions

Energy sealing without reinforcement allows secure treatment during lung resection of pulmonary arteries as large as 5 mm in diameter and pulmonary veins as large as 7 mm.  相似文献   
10.
目的探讨对肺癌胸腔镜术后患者行综合护理干预对于并发症以及生存质量的临床影响。方法抽取到本院接受治疗的132例肺癌胸腔镜术后患者,研究时间为2017年1月—2018年12月,将其按照双盲法分成综合组和对照组,分别为66例患者。综合组行综合护理措施,对照组行常规护理措施,观察两组患者的临床资料,并且比较两组患者的并发症以及生存质量。结果综合组患者接受护理后并发症发生率3例(4.55%),明显低于对照组11例(16.67%),综合组生存质量评分均高于对照组,P<0.05。结论对肺癌胸腔镜术后患者行综合护理干预,降低并发症的发几率,提高了生存质量。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号